<b>Conclusions:</b> This study reveals ZYBSW can effectively alleviate CGN, with EGFR and DUSP1 as likely therapeutic targets, and its mechanism of action primarily involves regulating the MAPK signaling pathway. This evidence concerns the gene DUSP1 and childhood gender nonconformity.